Chronic Exogenous Ketosis in HFpEF

NCT ID: NCT06937320

Last Updated: 2025-09-17

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-28
• Study Completion Date: 2027-06-30

Brief Summary

The goal of this clinical research study is to test what effects a ketone drink will have in people with heart failure with preserved ejection fraction (HFpEF), including on exercise and heart function. Patients with HFpEF often have difficulty exercising, and our goal is to understand whether a ketone drink changes much patients can exercise. The study has three visits, including a baseline visit to assess for study eligibility, and two visits (one after 8 weeks of a ketone drink or a placebo drink, and another one after 8 weeks of whichever drink the participant did not receive the first time).

Conditions

Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Normal Ejection Fraction; Heart Failure, Diastolic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Exogenous ketone drink

(R)-1,3-butanediol (commercially obtained as "KetoneIQ")

Group Type: EXPERIMENTAL

Exogenous Ketone Drink

Intervention Type: DIETARY_SUPPLEMENT

(R)-1,3-butanediol (BD, commercially available as "KetoneIQ") initially dosed 300 mg/kg BID (target dose 400 mg/kg grams BID if tolerated) for 8 weeks

Placebo

ketone-free solution

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

equi-volume placebo administered for 8 weeks

Interventions

Exogenous Ketone Drink

(R)-1,3-butanediol (BD, commercially available as "KetoneIQ") initially dosed 300 mg/kg BID (target dose 400 mg/kg grams BID if tolerated) for 8 weeks

Intervention Type: DIETARY_SUPPLEMENT

Placebo

equi-volume placebo administered for 8 weeks

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

(R)-1,3-butanediol; KetoneIQ; ketone

Eligibility Criteria

Inclusion Criteria

1. 18 years of age or older

2. Stable medical therapy for at least 2 weeks

3. New York Heart Association (NYHA) class symptoms II or III

4. Left ventricular ejection fraction ≥ 50%

5. Evidence for elevated filling pressures as follows (at least one of the following between a-d):

a. Mitral early (E)/mitral septal tissue annular (e') velocity ratio > 8 on echocardiography in addition to one of the following:

i. Enlarged left atrium (LA>4.0 cm width or LA volume index >34 mL/m2)

ii. Chronic loop diuretic use for control of symptoms

iii. Elevated natriuretic peptides within the past year (NT-proBNP>125 pg/ml or BNP>35 pg/ml)

b. Mitral E/e' ratio > 14 at rest or with exercise on echocardiography

c. Elevated invasively-determined filling pressures previously (resting left ventricular end-diastolic pressure >16 mm Hg or pulmonary capillary wedge pressure > 14 mmHg; or PCWP or LVEDP ≥ 25 mmHg with exercise)

d. Prior episode of acute heart failure requiring IV diuretics with evidence of volume overload on exam or radiology, or evidence of elevated natriuretic peptides.

Exclusion Criteria

1. Intentional ketogenic (high fat, low carbohydrate) diet in the last week

2. Cirrhosis or alcohol use disorder (>14 drinks/week).

3. Contraindications to stress testing, conditions that limit exercise, and other clinically-significant causes of exertional limitation (claudication with peripheral artery disease, atrial fibrillation and heart rate >110 at rest, systolic blood pressure>180 mmHg or diastolic blood pressure>110 mmHg, infiltrative/hypertrophic/inflammatory cardiomyopathy, clinically significant pericardial disease, joint or neuromuscular disease that precludes exercise, acute coronary syndrome within the last 2 months, estimated glomerular filtration rate<20 mL/min/1.73 m2, and hemoglobin < 9 mg/dL).

4. Clinically significant lung disease, defined as severe obstructive lung disease (Gold stage 3), a requirement for supplemental oxygen, or chronic obstructive pulmonary disease with an exacerbation requiring steroids or antibiotics within the last 2 months.

5. > Moderate aortic stenosis, >mild mitral stenosis, > moderate aortic or mitral regurgitation on screening echocardiogram, or presence of a prosthetic valve in the mitral position.

6. Type 1 diabetes mellitus

7. Start of a GLP-1 RA within the past 6 months.

8. Pregnant women.

9. Angina due to epicardial coronary disease or known presence of clinically-significant, unrevascularized epicardial coronary disease, in the investigator's opinion.

10. Prior reduced LVEF to < 45% by echocardiography or cardiac MRI

11. Participation in another clinical study with an investigational product in the previous 4 weeks prior to enrollment (or longer if deemed necessary by the investigator).

12. Conditions that may render the patient unable to complete the study, in the opinion of the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Senthil Selvaraj, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Duke University

Durham, North Carolina, United States

Countries

United States

Other Identifiers

Pro00117625

Identifier Type: -

Identifier Source: org_study_id